Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya

NCT07487077 is registered in ClinicalTrials.gov with Albert B. Sabin Vaccine Institute as lead sponsor.

NCT NCT07487077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07487077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya
Lead sponsor
Albert B. Sabin Vaccine Institute
Phase
Phase 4
Overall status
Recruiting
Start date
October 31, 2025
Completion date
June 30, 2028
Enrollment
1,071 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholera vaccination